Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8401178 | 0.81 | L3MBTL1 (0.48) | BTKDHODHMCL1XDHTNK2 | |
| SCHEMBL8401171 | 0.73 | GPR84 (0.43) | BTKXDHNPC1RAB9AADORA1 | |
| SCHEMBL8534916 | 0.70 | HPGD (0.43) | BTKMCL1XDHTNK2TDP1 | |
| SCHEMBL18780332 | 0.70 | BTK (0.57) | BTKMCL1XDHTNK2NPC1 | |
| SCHEMBL8401177 | 0.69 | BTK (0.51) | BTKXDHTNK2NPC1RAB9A | |
| SCHEMBL8534958 | 0.68 | KDM4E (0.51) | ADORA1ADORA2ATDP1 | |
| SCHEMBL8401168 | 0.67 | ALDH1A1 (0.53) | BTKADORA1ADORA2AMAPK1TDP1 | |
| SCHEMBL8401218 | 0.63 | L3MBTL1 (0.43) | NPC1RAB9AADORA1ADORA2A | |
| SCHEMBL8401200 | 0.63 | L3MBTL1 (0.49) | NPC1RAB9AADORA1ADORA2ATDP1 | |
| SCHEMBL20809296 | 0.62 | DHODH (0.54) | DHODHADORA3ADORA2BADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | BTK 1/4885DHODH 2962/4885MCL1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.